Dirk Kuypers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/261463/publications.pdf Version: 2024-02-01



NIDE KIIVDEDS

#	Article	IF	CITATIONS
1	Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 481-508.	4.5	1,178
2	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. Therapeutic Drug Monitoring, 2009, 31, 139-152.	2.0	398
3	Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. Journal of Medical Genetics, 2004, 41, e84-e84.	3.2	311
4	Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation. Therapeutic Drug Monitoring, 2006, 28, 145-154.	2.0	305
5	Diagnosis and prevention of chronic kidney allograft loss. Lancet, The, 2011, 378, 1428-1437.	13.7	279
6	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 341-358.	4.5	276
7	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation, 2004, 19, 1281-1287.	0.7	273
8	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1182-1189.	4.5	265
9	MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION. Transplantation, 2001, 71, 1282-1287.	1.0	246
10	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	1.0	238
11	EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME. Transplantation, 2001, 71, 515-523.	1.0	236
12	Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biology, 2018, 68-69, 44-66.	3.6	230
13	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. Transplantation, 2017, 101, S1-S56.	1.0	217
14	Three‥ear Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. American Journal of Transplantation, 2005, 5, 2521-2530.	4.7	208
15	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney International, 2004, 65, 1842-1849.	5.2	206
16	Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients. Transplantation, 2013, 95, 333-340.	1.0	203
17	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney International, 2018, 94, 964-973.	5.2	198
18	CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. Clinical Pharmacology and Therapeutics, 2007, 82, 711-725.	4.7	192

#	Article	IF	CITATIONS
19	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, l4923.	2.3	191
20	Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients. Transplantation, 2006, 82, 1074-1084.	1.0	187
21	Intrarenal Resistive Index after Renal Transplantation. New England Journal of Medicine, 2013, 369, 1797-1806.	27.0	185
22	The impact of uridine diphosphate–glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics, 2005, 78, 351-361.	4.7	171
23	Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, 1205-1213.	4.7	161
24	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics, 2004, 75, 434-447.	4.7	157
25	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1997-2004.	4.7	157
26	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2009, 31, 416-435.	2.0	146
27	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3479-3487.	6.1	144
28	Tertiary â€~Hyperphosphatoninism' Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1193-1200.	4.7	143
29	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 2003, 75, 665-672.	1.0	142
30	Twelve-Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2003, 25, 609-622.	2.0	134
31	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. Transplantation, 2001, 72, 1655-1661.	1.0	128
32	Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts. Journal of the American Society of Nephrology: JASN, 2009, 20, 2468-2480.	6.1	126
33	Recovery of Hyperphosphatoninism and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1829-1836.	4.5	124
34	The Histology of Kidney Transplant Failure. Transplantation, 2014, 98, 427-435.	1.0	124
35	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrology Dialysis Transplantation, 2005, 20, 1714-1720.	0.7	123
36	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metabolism Reviews, 2016, 48, 88-112.	3.6	119

#	Article	IF	CITATIONS
37	Bartter's and Gitelman's Syndromes: From Gene to Clinic. Nephron Physiology, 2004, 96, p65-p78.	1.2	117
38	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Reviews, 2011, 25, 47-57.	2.9	116
39	The P450 oxidoreductase <i>*28</i> SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics, 2011, 12, 1281-1291.	1.3	116
40	Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. American Journal of Transplantation, 2016, 16, 3192-3201.	4.7	116
41	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. Kidney International, 2019, 95, 188-198.	5.2	116
42	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. Clinical Pharmacology and Therapeutics, 2009, 86, 319-327.	4.7	112
43	PREDICTORS OF RENAL TRANSPLANT HISTOLOGY AT THREE MONTHS. Transplantation, 1999, 67, 1222-1230.	1.0	111
44	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenetics and Genomics, 2008, 18, 339-348.	1.5	110
45	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney International, 2014, 85, 636-640.	5.2	106
46	The Influence of CKD on Colonic Microbial Metabolism. Journal of the American Society of Nephrology: JASN, 2016, 27, 1389-1399.	6.1	106
47	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. Artificial Organs, 2006, 30, 276-284.	1.9	105
48	Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients. Therapeutic Drug Monitoring, 2010, 32, 394-404.	2.0	103
49	Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leukemia and Lymphoma, 2013, 54, 2433-2440.	1.3	103
50	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. Clinical Pharmacokinetics, 2004, 43, 741-762.	3.5	102
51	High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. American Journal of Transplantation, 2016, 16, 2954-2963.	4.7	102
52	Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. American Journal of Transplantation, 2019, 19, 763-780.	4.7	102
53	Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clinical Therapeutics, 2008, 30, 673-683.	2.5	100
54	In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients. Clinical Pharmacology and Therapeutics, 2012, 92, 366-375.	4.7	100

#	Article	IF	CITATIONS
55	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. Journal of Clinical Pharmacology, 2003, 43, 866-880.	2.0	99
56	Management of polyomavirus-associated nephropathy in renal transplant recipients. Nature Reviews Nephrology, 2012, 8, 390-402.	9.6	98
57	Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 2193-2204.	6.1	98
58	Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrology Dialysis Transplantation, 2007, 22, 1730-1737.	0.7	96
59	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1268-1276.	4.5	96
60	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1508-1514.	4.5	93
61	Benefit-Risk Assessment of Sirolimus in Renal Transplantation. Drug Safety, 2005, 28, 153-181.	3.2	92
62	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrology Dialysis Transplantation, 2004, 19, 1895-1901.	0.7	83
63	The Predictive Value of Kidney Allograft Baseline Biopsies for Long-Term Graft Survival. Journal of the American Society of Nephrology: JASN, 2013, 24, 1913-1923.	6.1	83
64	Detoxifying Capacity and Kinetics of Prometheus [®] – A New Extracorporeal System for the Treatment of Liver Failure. Blood Purification, 2005, 23, 349-358.	1.8	82
65	Tacrolimus Exposure and Evolution of Renal Allograft Histology in the First Year After Transplantation. American Journal of Transplantation, 2007, 7, 2114-2123.	4.7	82
66	The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation, 2009, 24, 2269-2276.	0.7	81
67	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 71-79.	2.0	81
68	Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clinical Pharmacology and Therapeutics, 2020, 107, 347-358.	4.7	80
69	Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study. Transplantation, 2004, 78, 1204-1211.	1.0	79
70	Skin problems in chronic kidney disease. Nature Reviews Nephrology, 2009, 5, 157-170.	9.6	77
71	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. PLoS ONE, 2015, 10, e0140820.	2.5	77
72	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. EBioMedicine, 2019, 46, 463-472.	6.1	75

#	Article	IF	CITATIONS
73	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0153893.	2.5	74
74	Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 509-521.	4.7	73
75	Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenetics and Genomics, 2008, 18, 861-868.	1.5	72
76	Calcium Metabolism in the Early Posttransplantation Period. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 665-672.	4.5	72
77	Reduced CO Concentrations and Increased Dose Requirements in Renal Allograft Recipients Converted to the Novel Once-Daily Tacrolimus Formulation. Transplantation, 2010, 90, 523-529.	1.0	72
78	Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase. Clinical Pharmacology and Therapeutics, 2005, 78, 81-88.	4.7	71
79	Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report. Therapeutic Drug Monitoring, 2001, 23, 717-721.	2.0	70
80	Subclinical Peritubular Capillaritis at 3 Months Is Associated With Chronic Rejection at 1 Year. Transplantation, 2007, 83, 1416-1422.	1.0	70
81	An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes. American Journal of Transplantation, 2009, 9, 374-381.	4.7	70
82	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrology Dialysis Transplantation, 2004, 19, 469-473.	0.7	69
83	The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica, 2013, 98, 771-775.	3.5	69
84	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation, 2019, 103, 1953-1963.	1.0	69
85	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	1.9	68
86	Immunotherapy in Elderly Transplant Recipients. Drugs and Aging, 2009, 26, 715-737.	2.7	68
87	FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Neurobiology of Aging, 2015, 36, 1559-1568.	3.1	68
88	Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. American Journal of Transplantation, 2017, 17, 1853-1867.	4.7	68
89	Kidney Fibrosis. Transplantation, 2017, 101, 713-726.	1.0	67
90	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	6.1	67

#	Article	IF	CITATIONS
91	Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplantation Reviews, 2011, 25, 78-89.	2.9	66
92	Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. American Journal of Transplantation, 2019, 19, 3100-3113.	4.7	66
93	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1822-1831.	4.7	65
94	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrology Dialysis Transplantation, 2008, 23, 2033-2042.	0.7	65
95	European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs. Transplant International, 2011, 24, 1135-1141.	1.6	65
96	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplantation Reviews, 2011, 25, 58-64.	2.9	65
97	Factors influencing technical success and outcome of percutaneous balloon angioplasty in de novo native hemodialysis arteriovenous fistulas. European Journal of Radiology, 2012, 81, 2298-2303.	2.6	65
98	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. Journal of the American Society of Nephrology: JASN, 2016, 27, 281-292.	6.1	65
99	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. International Journal of Pharmaceutics, 2013, 452, 14-35.	5.2	63
100	Bone mineral density, bone turnover markers, andÂincident fractures in de novo kidney transplantÂrecipients. Kidney International, 2019, 95, 1461-1470.	5.2	61
101	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. American Journal of Kidney Diseases, 2002, 39, 315-323.	1.9	60
102	Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transplant International, 2005, 18, 140-150.	1.6	60
103	Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. American Journal of Transplantation, 2017, 17, 2372-2380.	4.7	60
104	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Journal of the American Society of Nephrology: JASN, 2020, 31, 2168-2183.	6.1	60
105	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1525-1533.	4.5	59
106	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. American Journal of Transplantation, 2002, 2, 989-992.	4.7	58
107	Criteria for HNF1B analysis in patients with congenital abnormalities of kidney and urinary tract. Nephrology Dialysis Transplantation, 2015, 30, 835-842.	0.7	57
108	Metabolism, Protein Binding, and Renal Clearance of Microbiota–Derived p-Cresol in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1136-1144.	4.5	57

#	Article	IF	CITATIONS
109	Pharmacogenetics in solid organ transplantation: current status and future directions. Transplantation Reviews, 2008, 22, 6-20.	2.9	56
110	Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure. American Journal of Transplantation, 2013, 13, 86-99.	4.7	56
111	Renal cortical nephrocalcinosis. Nephrology Dialysis Transplantation, 2000, 15, 1080-1082.	0.7	54
112	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clinical Transplantation, 2003, 17, 234-241.	1.6	54
113	The value of tuberculin skin testing in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 433-438.	0.7	54
114	Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. American Journal of Transplantation, 2020, 20, 3367-3378.	4.7	54
115	The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. Transplantation, 2007, 84, 362-373.	1.0	52
116	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney International, 2015, 87, 210-216.	5.2	52
117	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. Nephron Clinical Practice, 2008, 110, c80-c85.	2.3	51
118	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transplant International, 2013, 26, 813-821.	1.6	51
119	Can antibody prophylaxis allow sparing of other immunosuppressives?. Transplantation Proceedings, 1999, 31, 1246-1248.	0.6	50
120	Genome-Wide Association Study of Acute Renal Graft Rejection. American Journal of Transplantation, 2017, 17, 201-209.	4.7	50
121	DIFFERENCES IN GASTRIC MOTOR ACTIVITY IN RENAL TRANSPLANT RECIPIENTS TREATED WITH FK-506 VERSUS CYCLOSPORINE. Transplantation, 1999, 68, 1482-1485.	1.0	50
122	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. Transplantation, 2010, 89, 595-599.	1.0	48
123	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrology, 2014, 15, 87.	1.8	48
124	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. British Journal of Clinical Pharmacology, 2015, 80, 548-559.	2.4	48
125	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. Transplantation, 2003, 76, 102-108.	1.0	47
126	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation, 2018, 18, 1726-1734.	4.7	47

#	Article	IF	CITATIONS
127	Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. American Journal of Kidney Diseases, 2004, 43, e24.1-e24.5.	1.9	46
128	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. American Journal of Transplantation, 2009, 9, 2470-2478.	4.7	46
129	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics Journal, 2015, 15, 144-152.	2.0	46
130	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. Blood Purification, 2003, 21, 244-252.	1.8	44
131	Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. Pharmacogenetics and Genomics, 2014, 24, 597-606.	1.5	44
132	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. American Journal of Transplantation, 2015, 15, 2900-2907.	4.7	43
133	Acute rejection in non-compliant renal allograft recipients: a distinct morphology. Clinical Transplantation, 2007, 21, 344-351.	1.6	41
134	Cutaneous phaeohyphomycosis in renal allograft recipients: report of 2 cases and review of the literature. Diagnostic Microbiology and Infectious Disease, 2010, 68, 177-180.	1.8	41
135	Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies. Transplantation, 2017, 101, 1924-1934.	1.0	41
136	AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. Therapeutic Drug Monitoring, 2008, 30, 439-444.	2.0	40
137	Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 329-341.	3.5	40
138	A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clinical Therapeutics, 2010, 32, 2012-2023.	2.5	40
139	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. Journal of the American Society of Nephrology: JASN, 2021, 32, 397-409.	6.1	40
140	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrology Dialysis Transplantation, 2002, 17, 923-926.	0.7	38
141	Recurrence of glomerulonephritis after renal transplantation. Transplantation Reviews, 2013, 27, 126-134.	2.9	38
142	Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. American Journal of Transplantation, 2013, 13, 1746-1756.	4.7	38
143	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney International, 2014, 85, 1434-1443.	5.2	38
144	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. Clinical Infectious Diseases, 2015, 60, 1505-1511.	5.8	38

#	Article	IF	CITATIONS
145	Missing Self–Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 2070-2082.	6.1	38
146	Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity. Transplantation, 2011, 91, 1098-1102.	1.0	37
147	Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplantation Reviews, 2017, 31, 69-77.	2.9	37
148	Posttransplant Epstein-Barr Virus-Associated Myogenic Tumors: Case Report and Review of the Literature. American Journal of Transplantation, 2008, 8, 253-258.	4.7	36
149	In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients. Clinical Pharmacology and Therapeutics, 2011, 90, 414-422.	4.7	36
150	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clinical Transplantation, 2012, 26, 393-402.	1.6	36
151	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transplant International, 2013, 26, 973-981.	1.6	36
152	High Rate of Charcot Foot Attacks Early After Simultaneous Pancreas???Kidney Transplantation. Transplantation, 2007, 83, 245-246.	1.0	35
153	The influence of renal transplantation on retained microbial–human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35
154	Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients. Therapeutic Drug Monitoring, 2017, 39, 77-82.	2.0	35
155	Assessing the Complex Causes of Kidney Allograft Loss. Transplantation, 2020, 104, 2557-2566.	1.0	35
156	Fungal infections in solid organ transplantation: An update on diagnosis and treatment. Transplantation Reviews, 2019, 33, 77-86.	2.9	34
157	Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. American Journal of Transplantation, 2021, 21, 2413-2423.	4.7	34
158	Hypotrichosisâ€lymphedemaâ€ŧelangiectasiaâ€ŧenal defect associated with a truncating mutation in the <scp>SOX18</scp> gene. Clinical Genetics, 2015, 87, 378-382.	2.0	33
159	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clinica Chimica Acta, 2008, 389, 87-92.	1.1	32
160	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrology Dialysis Transplantation, 2016, 31, 1508-1514.	0.7	32
161	Stenosis Detection in Native Hemodialysis Fistulas with MDCT Angiography. American Journal of Roentgenology, 2009, 192, 1079-1084	2.2	31
162	Impact of <i>CYP3A5</i> genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics, 2013, 14, 1467-1480.	1.3	31

#	Article	IF	CITATIONS
163	Antibodies Against ARHGDIB and ARHGDIB Gene Expression Associate With Kidney Allograft Outcome. Transplantation, 2020, 104, 1462-1471.	1.0	31
164	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. American Journal of Kidney Diseases, 2005, 45, e33-e37.	1.9	30
165	Donor-specific antibodies require preactivated immune system to harm renal transplant. EBioMedicine, 2016, 9, 366-371.	6.1	30
166	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. British Journal of Dermatology, 2007, 158, 071018053044006-???.	1.5	29
167	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. Journal of Antimicrobial Chemotherapy, 2008, 63, 417-419.	3.0	29
168	Tacrolimus-Induced Neutropenia in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 690-694.	4.5	29
169	Technology Experience of Solid Organ Transplant Patients and Their Overall Willingness to Use Interactive Health Technology. Journal of Nursing Scholarship, 2018, 50, 151-162.	2.4	29
170	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metabolism and Disposition, 2004, 32, 1421-1425.	3.3	28
171	The Functional Implications of Common Genetic Variation in <i>CYP3A5</i> and <i>ABCB1</i> in Human Proximal Tubule Cells. Molecular Pharmaceutics, 2015, 12, 758-768.	4.6	28
172	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. Journal of the American Society of Nephrology: JASN, 2021, 32, 1084-1096.	6.1	28
173	Limited cutaneous systemic sclerosis associated with MPO-ANCA positive renal small vessel vasculitis of the microscopic polyangiitis type. American Journal of Kidney Diseases, 2000, 36, e16.1-e16.5.	1.9	27
174	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. Blood Purification, 2005, 23, 101-105.	1.8	27
175	Immunosuppression: Does One Regimen Fit All?. Transplantation, 2011, 92, 251-261.	1.0	27
176	Histological characteristics of Acute Tubular Injury during Delayed Graft Function predict renal function after renal transplantation. Physiological Reports, 2019, 7, e14000.	1.7	26
177	â€ [~] Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrology Dialysis Transplantation, 2001, 16, 2258-2262.	0.7	25
178	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. American Journal of Kidney Diseases, 2022, 79, 667-676.e1.	1.9	25
179	Renal transplantation onto abnormal urinary tract: ileal conduit urinary diversion. Transplantation Proceedings, 2001, 33, 2493-2494.	0.6	24
180	Combined 'En Bloc' Liver and Pancreas Transplantation in Patients with Liver Disease and Type 1 Diabetes Mellitus. American Journal of Transplantation, 2004, 4, 1921-1927.	4.7	24

#	Article	IF	CITATIONS
181	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. Transplant International, 2007, 20, 381-385.	1.6	24
182	Comparative performance of oral midazolam clearance and plasma 4βâ€hydroxycholesterol to explain interindividual variability in tacrolimus clearance. British Journal of Clinical Pharmacology, 2016, 82, 1539-1549.	2.4	24
183	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2085-2092.	4.5	23
184	Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplantation Reviews, 2011, 25, 65-77.	2.9	23
185	Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transplant International, 2012, 25, 391-400.	1.6	23
186	Kidney donation after circulatory death in a country with a high number of brain dead donors: 10-year experience in Belgium. Transplant International, 2012, 25, 857-866.	1.6	23
187	From Nonadherence to Adherence. Transplantation, 2020, 104, 1330-1340.	1.0	23
188	Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clinical Transplantation, 2005, 19, 475-482.	1.6	22
189	Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. British Journal of Clinical Pharmacology, 2007, 63, 541-547.	2.4	22
190	The Once-Daily Formulation of Tacrolimus. Transplantation, 2012, 93, 241-243.	1.0	22
191	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenetics and Genomics, 2012, 22, 399-407.	1.5	22
192	Resolution of diffuse skin and systemic <scp>K</scp> aposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report. Transplant Infectious Disease, 2015, 17, 303-307.	1.7	22
193	The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study. Transplant Immunology, 2018, 50, 55-59.	1.2	22
194	IgA antiglomerular basement membrane disease associated with bronchial carcinoma and monoclonal gammopathy. American Journal of Kidney Diseases, 1999, 33, e3.1-e3.5.	1.9	21
195	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. Transplantation, 2005, 79, 737.	1.0	21
196	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. Transplantation, 2006, 81, 1750-1752.	1.0	21
197	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparinâ€Induced Thrombocytopenia: Doseâ€Finding Study and Safety Evaluation. Artificial Organs, 2013, 37, 482-487.	1.9	21
198	Telomere length, cardiovascular risk and arteriosclerosis in human kidneys: an observational cohort study. Aging, 2015, 7, 766-775.	3.1	21

#	Article	IF	CITATIONS
199	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation, 2016, 100, 2188-2193.	1.0	21
200	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrology Dialysis Transplantation, 2020, 35, 697-705.	0.7	21
201	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. Therapeutic Drug Monitoring, 2003, 25, 447-451.	2.0	20
202	Preoperative Mapping for Haemodialysis Access Surgery with CO2 Venography of the Upper Limb. European Journal of Vascular and Endovascular Surgery, 2010, 39, 340-345.	1.5	20
203	Renal Cell Carcinoma in the Allograft: What Is the Role of Polyomavirus. Case Reports in Nephrology and Urology, 2012, 2, 125-134.	1.5	20
204	Completeness and Satisfaction with the Education and Information Received by Patients Immediately after Kidney Transplant: A Mixed-Models Study. Progress in Transplantation, 2013, 23, 12-22.	0.7	20
205	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. Nephrology Dialysis Transplantation, 2017, 32, 707-714.	0.7	20
206	Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 73, e661-e671.	5.8	20
207	Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method. Therapeutic Drug Monitoring, 2009, 31, 218-223.	2.0	19
208	Prevalence and determinants of anemia in the immediate postkidney transplant period. Transplant International, 2011, 24, 1208-1215.	1.6	19
209	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. American Journal of Transplantation, 2013, 13, 1910-1914.	4.7	19
210	Genetic polymorphisms in <i><scp>IL</scp>â€2</i> , <i><scp>IL</scp>â€10</i> , <i><scp>TGF</scp>â€</i> ^i>î² <i>1 and <i><scp>IL</scp>â€2<scp>RB</scp></i> and acute rejection in renal transplant patients. Clinical Transplantation, 2014, 28, 649-655.</i>	:/i>, 1.6	19
211	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. Diabetes Care, 2019, 42, 625-634.	8.6	19
212	Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies. Kidney International, 2021, 100, 401-414.	5.2	19
213	Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment. Nephrology Dialysis Transplantation, 1999, 14, 2050-2051.	0.7	18
214	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplantation Proceedings, 2002, 34, 1164-1170.	0.6	18
215	Secondary effects of immunosuppressive drugs after simultaneous pancreas–kidney transplantation. Nephrology Dialysis Transplantation, 2005, 20, ii33-ii39.	0.7	18
216	Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Annals of the Rheumatic Diseases, 2009, 68, 759-761.	0.9	18

#	Article	IF	CITATIONS
217	A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomedical Chromatography, 2011, 25, 1091-1098.	1.7	18
218	Occupational Radiation Dose: Percutaneous Interventional Procedures on Hemodialysis Arteriovenous Fistulas and Grafts. Radiology, 2012, 264, 278-284.	7.3	18
219	Charcot neuroarthropathy after simultaneous pancreas–kidney transplantation: risk factors, prevalence, and outcome. Clinical Transplantation, 2015, 29, 712-719.	1.6	18
220	ADHERE: randomized controlled trial comparing renal function in <i>de novo</i> kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transplant International, 2017, 30, 83-95.	1.6	18
221	Monoclonal antibodies in renal transplantation: old and new. Nephrology Dialysis Transplantation, 2004, 19, 297-300.	0.7	17
222	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 4044-4048.	0.7	17
223	Balancing Efficacy and Toxicity of Kidney Transplant Immunosuppression. Transplantation Proceedings, 2009, 41, 3393-3395.	0.6	17
224	Microscopic nephrocalcinosis in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 843-848.	0.7	17
225	<i>Mycobacterium genavense</i> infection in a solid organ recipient: a diagnostic and therapeutic challenge. Transplant Infectious Disease, 2016, 18, 125-131.	1.7	17
226	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. Drug Metabolism and Disposition, 2018, 46, 1507-1513.	3.3	17
227	Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis. Kidney International, 2019, 96, 1195-1204.	5.2	17
228	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. Therapeutic Drug Monitoring, 2011, 33, 155-164.	2.0	17
229	Social Reinforcement and Remedial Instruction in the Elimination of a Classroom Behavior Problem. Journal of Special Education, 1968, 2, 291-305.	1.7	16
230	Secondary Renal Amyloidosis due to Long-Standing Tubulointerstitial Nephritis in a Patient With Sjögren Syndrome. American Journal of Kidney Diseases, 2005, 46, e75-e80.	1.9	16
231	Apparent Elevation of Cyclosporine Whole Blood Concentrations in a Renal Allograft Recipient. Therapeutic Drug Monitoring, 2010, 32, 529-531.	2.0	16
232	Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype. Pharmacogenomics Journal, 2017, 17, 556-562.	2.0	16
233	Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort. Nephrology Dialysis Transplantation, 2021, 36, 918-926.	0.7	16
234	Prophylaxis of cytomegalovirus infection in renal transplantation. Nephrology Dialysis Transplantation, 1998, 13, 3012-3016.	0.7	15

#	Article	IF	CITATIONS
235	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. Transplantation, 2001, 72, 1165-1166.	1.0	15
236	Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings. Frontiers in Immunology, 2022, 13, 818569.	4.8	15
237	Tailoring immunosuppressive therapy. Nephrology Dialysis Transplantation, 2002, 17, 2051-2054.	0.7	14
238	Immunosuppressive Drug Therapy and Subclinical Acute Renal Allograft Rejection: Impact and Effect. Transplantation, 2008, 85, S25-S30.	1.0	14
239	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrology Dialysis Transplantation, 2016, 31, 1515-1522.	0.7	14
240	Repeated kidney reâ€ŧransplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis. Transplant International, 2020, 33, 617-631.	1.6	14
241	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. American Journal of Nephrology, 2012, 35, 24-30.	3.1	13
242	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. Kidney International, 2014, 86, 1001-1006.	5.2	13
243	Pretransplant 4βâ€hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2406-2415.	2.4	13
244	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney International Reports, 2020, 5, 627-631.	0.8	13
245	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clinical Transplantation, 2003, 17, 171-176.	1.6	12
246	Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. Clinical Therapeutics, 2004, 26, 1834-1844.	2.5	12
247	Urinary Connective Tissue Growth Factor Is Associated with Human Renal Allograft Fibrogenesis. Transplantation, 2013, 96, 494-500.	1.0	12
248	Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. Transplantation, 2014, 98, 451-457.	1.0	12
249	Natural History of Bone Disease following Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 638-652.	6.1	12
250	Intracerebral haemorrhage caused by cefazolineâ€induced hypoprothrombinaemia in a renal transplant recipient. Nephrology Dialysis Transplantation, 2002, 17, 532-533.	0.7	11
251	Pseudoaneurysm Complicating Protocol Renal Transplant Biopsies: Case Reports. Transplantation Proceedings, 2008, 40, 1397-1398.	0.6	11
252	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. Transplantation, 2010, 89, 341-346.	1.0	11

#	Article	IF	CITATIONS
253	Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients. Transplantation, 2011, 92, 321-327.	1.0	11
254	Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. British Journal of Clinical Pharmacology, 2017, 83, 863-874.	2.4	11
255	Patterns of renal osteodystrophy 1 year after kidney transplantation. Nephrology Dialysis Transplantation, 2021, 36, 2130-2139.	0.7	11
256	The evolution of histological changes suggestive of antibodyâ€mediated injury, in the presence and absence of donorâ€specific antiâ€HLA antibodies. Transplant International, 2021, 34, 1824-1836.	1.6	11
257	Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem. Nephrology Dialysis Transplantation, 1999, 14, 2304-2308.	0.7	10
258	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. Transplantation Proceedings, 2005, 37, 2840-2842.	0.6	10
259	Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients. Clinical Pharmacology and Therapeutics, 2010, 88, 595-596.	4.7	10
260	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. Nephrology Dialysis Transplantation, 2014, 29, 1965-1972.	0.7	10
261	Noncutaneous head and neck cancer in solid organ transplant patients: Single center experience. Oral Oncology, 2014, 50, 263-268.	1.5	10
262	Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. Transplant International, 2017, 30, 695-705.	1.6	10
263	Fexofenadine, a Putative <i>In Vivo</i> Pâ€glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. Clinical Pharmacology and Therapeutics, 2017, 102, 989-996.	4.7	10
264	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. CKJ: Clinical Kidney Journal, 2021, 14, 1901-1907.	2.9	10
265	Histological injury and renal transplant outcome: the cumulative damage hypothesis. Transplantation Proceedings, 2001, 33, 1149-1150.	0.6	9
266	C4d deposition in the peritubular capillaries of native renal biopsies. Histopathology, 2005, 47, 430-432.	2.9	9
267	The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. PLoS Medicine, 2020, 17, e1003140.	8.4	9
268	Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation. Scientific Reports, 2021, 11, 15606.	3.3	9
269	Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. Kidney International, 2022, 102, 183-195.	5.2	9
270	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. Transplant International, 0, 35, .	1.6	9

#	Article	IF	CITATIONS
271	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. Journal of Antimicrobial Chemotherapy, 2005, 55, 391-394.	3.0	8
272	Subacute cytomegalovirus appendicitis in a renal transplant recipient. Transplant Infectious Disease, 2013, 15, 96-97.	1.7	8
273	CHRONIC WOUNDS IN A KIDNEY TRANSPLANT RECIPIENT WITH MODERATE RENAL IMPAIRMENT. Acta Clinica Belgica, 2013, 68, 128-131.	1.2	8
274	Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid. Transplantation, 2016, 100, e50-e51.	1.0	8
275	Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss. Antiviral Research, 2019, 168, 203-209.	4.1	8
276	Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation. Frontiers in Immunology, 2020, 11, 1886.	4.8	8
277	Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation. Nephrology Dialysis Transplantation, 2006, 21, 3306-3310.	0.7	7
278	The Histological Picture of Indication Biopsies in the First 2 Weeks after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1484-1493.	4.5	7
279	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. Bone, 2021, 152, 116066.	2.9	7
280	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. Transplantation, 2022, 106, 1215-1226.	1.0	7
281	Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Nephrology Dialysis Transplantation, 2021, 36, 884-889.	0.7	7
282	Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. Nephrology Dialysis Transplantation, 2022, 37, 1384-1386.	0.7	7
283	The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation. Frontiers in Immunology, 2022, 13, 809059.	4.8	7
284	Forecasting of Patient-Specific Kidney Transplant Function With a Sequence-to-Sequence Deep Learning Model. JAMA Network Open, 2021, 4, e2141617.	5.9	7
285	Renal transplantation for end-stage renal disease due to paroxysmal nocturnal haemoglobinuria. Nephrology Dialysis Transplantation, 1998, 13, 3250-3252.	0.7	6
286	Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a Single-Center experience. Transplantation Proceedings, 2003, 35, S138-S142.	0.6	6
287	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. Transplantation, 2010, 89, 1296-1297.	1.0	6
288	Emerging Immunosuppressive Drugs in Kidney Transplantation. Current Clinical Pharmacology, 2011, 6, 130-136.	0.6	6

#	Article	IF	CITATIONS
289	Everolimus in acute kidney injury in a patient with breast cancer: a case report. Journal of Medical Case Reports, 2014, 8, 386.	0.8	6
290	Replicative senescence and arteriosclerosis after kidney transplantation. Nephrology Dialysis Transplantation, 2020, 35, 1984-1995.	0.7	6
291	Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay. Nephrology Dialysis Transplantation, 2020, 35, 1328-1337.	0.7	6
292	Association of Predicted HLA T-Cell Epitope Targets and T-Cell–Mediated Rejection After Kidney Transplantation. American Journal of Kidney Diseases, 2022, 80, 718-729.e1.	1.9	6
293	Oral quinine pharmacokinetics and dietary salt intake. European Journal of Clinical Pharmacology, 2001, 57, 111-113.	1.9	5
294	Alemtuzumab induction therapy in kidney transplantation. Lancet, The, 2014, 384, 1649-1651.	13.7	5
295	Rhodococcus equi Sepsis in a Renal Transplant Recipient. Transplantation Direct, 2015, 1, 1-6.	1.6	5
296	Longâ€term, prolongedâ€release tacrolimusâ€based immunosuppression in de novo kidney transplant recipients: 5â€year prospective followâ€up of the ADHERE study patients. Transplant International, 2020, 33, 161-173.	1.6	5
297	A young patient with unexplained acute hepatorenal dysfunction. Nephrology Dialysis Transplantation, 2003, 18, 1220-1222.	0.7	4
298	KIDNEY TRANSPLANTATION: CURRENT ISSUES AND FUTURE PROSPECTS. Acta Clinica Belgica, 2007, 62, 208-217.	1.2	4
299	Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter?. American Journal of Kidney Diseases, 2018, 71, 302-305.	1.9	4
300	"What do we know about tacrolimus pharmacogenetics in transplant recipients?â€ . Pharmacogenomics, 2018, 19, 593-597.	1.3	4
301	In vivo <scp>CYP</scp> 3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 50-55.	2.5	4
302	The effect of IGL-1 preservation solution on outcome after kidney transplantation: A retrospective single-center analysis. American Journal of Transplantation, 2021, 21, 830-837.	4.7	4
303	Polyomavirus interstitial nephritis and concurrent post-transplant lymphoma in a renal allograft: coincidence or more?. Transplant International, 2005, 18, 1304-1307.	1.6	3
304	Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan®). Nephrology Dialysis Transplantation, 2005, 20, 1516-1517.	0.7	3
305	Therapeutic drug monitoring of mycophenolates: why make simple things complicated?. Transplantation Reviews, 2011, 25, 45-46.	2.9	3
306	The Bumpy Road of Genomic Medicine in Transplantation. Transplantation, 2012, 93, 578-579.	1.0	3

#	Article	IF	CITATIONS
307	Response to: â€~Bodyweightâ€adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. British Journal of Clinical Pharmacology, 2017, 83, 1353-1356.	2.4	3
308	Kuypers and Vanhove reply to †Was 4βâ€hydroxycholesterol ever going to be a useful marker of <scp>CYP3A4</scp> activity?' by Neuhoff and Tucker. British Journal of Clinical Pharmacology, 2018, 84, 1622-1623.	2.4	3
309	Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series. Transplantation, 2020, 104, 184-189.	1.0	3
310	The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidates. Journal of Viral Hepatitis, 2021, 28, 105-111.	2.0	3
311	Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography – tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114296.	2.8	3
312	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. Acta Clinica Belgica, 2013, 68, 215-217.	1.2	2
313	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. CardioRenal Medicine, 2020, 10, 402-414.	1.9	2
314	Hyperhomocysteinemia: a trigger for complement-mediated TMA?. Acta Clinica Belgica, 2021, 76, 65-69.	1.2	2
315	Data and optimisation requirements for Kidney Exchange Programs. Health Informatics Journal, 2021, 27, 146045822110099.	2.1	2
316	Liver and/or Kidney Transplantation After SARS-CoV-2 Infection. Transplantation, 2021, Publish Ahead of Print, .	1.0	2
317	Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2021, 76, 3322-3325.	3.0	2
318	Predicting modelâ€informed precision dosing: A testâ€case in tacrolimus dose adaptation for kidney transplant recipients. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	2.5	2
319	An uncommon tumor in a renal graft recipient: A diagnostic and therapeutic challenge. American Journal of Kidney Diseases, 2002, 40, e21.1-e21.6.	1.9	1
320	An unusual cause of ureteral obstruction in a renal allograft. Nephrology Dialysis Transplantation, 2006, 21, 3593-3594.	0.7	1
321	The Economic Burden of Post-Transplant Events in Renal Transplant Patients in Belgium (The PORTRAIT) Tj ETQq1	1,0,7843 1,0	914 rgBT /O
322	Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejecton and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results. Transplantation, 2012, 94, 980.	1.0	1
323	Response to "CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients― Clinical Pharmacology and Therapeutics, 2013, 94, 202-203.	4.7	1
324	Response to "Pretransplantation Pharmacokinetic Assessments to Predict Posttransplantation Dosing Requirements in Renal Transplant Recipients: What Is Known?― Clinical Pharmacology and Therapeutics, 2013, 93, 307-308.	4.7	1

#	Article	IF	CITATIONS
325	Response to â€~Tacrolimus pharmacokinetics after kidney transplantation – Influence of changes in haematocrit and steroid dose'. British Journal of Clinical Pharmacology, 2015, 80, 1473-1474.	2.4	1
326	Predictive Modeling of Tacrolimus Dose Requirements: "All That Is Gold Does Not Glitter― American Journal of Transplantation, 2017, 17, 1144-1145.	4.7	1
327	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. CKJ: Clinical Kidney Journal, 2020, 13, 906-908.	2.9	1
328	Acquired Perforating Disorders. , 2015, , 113-117.		1
329	Improve in-depth immunological risk assessment to optimize genetic-compatibility and clinical outcomes in child and adolescent recipients of parental donor kidney transplants: protocol for the INCEPTION study. BMC Nephrology, 2021, 22, 416.	1.8	1
330	Polyomavirus BK Genome Comparison Shows High Genetic Diversity in Kidney Transplant Recipients Three Months after Transplantation. Viruses, 2022, 14, 1533.	3.3	1
331	Dialysis Techniques in the Critic Ally-III Patient. Acta Clinica Belgica, 2000, 55, 237-243.	1.2	0
332	Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. Lancet, The, 2003, 361, 969.	13.7	0
333	Acute kidney failure and an epigastric mass. CKJ: Clinical Kidney Journal, 2009, 2, 78-79.	2.9	0
334	Research Highlights. Pharmacogenomics, 2010, 11, 9-12.	1.3	0
335	Organ transplantation after cardiac death. Lancet, The, 2011, 377, 203.	13.7	0
336	Urinary Connective Tissue Growth Factor (CTGFu) as a Marker and Early Predictor of Chronic Renal Allograft Injury. Transplantation, 2012, 94, 82.	1.0	0
337	Recipients' Smoking Habits and Death-Censored Renal Allograft Survival. Transplantation, 2012, 94, 24.	1.0	0
338	In Vivo CYP3A4-Activity, CYP3A5-Genotype and Hematocrit Predict Tacrolimus Dose-Requirements and Clearance in Renal Transplant Recipients. Transplantation, 2012, 94, 248-249.	1.0	0
339	Research Highlights: Highlights from the latest articles in transplantation pharmacogenomics. Pharmacogenomics, 2012, 13, 1679-1683.	1.3	0
340	Prof. Dr Yves Vanrenterghem. Nephrology Dialysis Transplantation, 2013, 28, 2919-2920.	0.7	0
341	Professor Dr Yves Vanrenterghem. Transplantation, 2014, 97, 125-126.	1.0	0
342	P882 COMBINED OR NOT COMBINED LIVER/KIDNEY TRANSPLANTATION FOR SYMPTOMATIC POLYCYSTIC LIVER DISEASE: SINGLE CENTER LONG-TERM OUTCOME EXPERIENCE. Journal of Hepatology, 2014, 60, S367-S368.	3.7	0

#	Article	IF	CITATIONS
343	SP691THE SOLUBLE UROKINASE RECEPTOR (SUPAR) PREDICTS MORTALITY IN END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2015, 30, iii607-iii607.	0.7	0
344	P136 De novo HLA antibodies with similar specificities in three recipients from the same deceased organ donor. Human Immunology, 2016, 77, 137.	2.4	0
345	MO020AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, CYTOPENIA AND POSTTRANSPLANT OUTCOMES: A RETROSPECTIVE ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
346	CAUSE OF DEATH AS A RISK FACTOR FOR IMMEDIATE AND LONG-TERM FUNCTIONAL OUTCOME OF RENAL ALLOGRAFTS FROM CADAVERIC DONORS. Transplantation, 1999, 67, S553.	1.0	0
347	Intrarenal arteriosclerosis and telomere attrition associate with dysregulation of the cholesterol pathway. Aging, 2020, 12, 7830-7847.	3.1	0
348	Title is missing!. , 2020, 17, e1003140.		0
349	Title is missing!. , 2020, 17, e1003140.		0
350	Title is missing!. , 2020, 17, e1003140.		0
351	Title is missing!. , 2020, 17, e1003140.		0
352	Title is missing!. , 2020, 17, e1003140.		0
353	Title is missing!. , 2020, 17, e1003140.		0
354	Infection-Related Nephropathies: Hepatitis C Virus. , 0, , 272-276.		0